Cara Therapeutics Inc. (NASDAQ: CARA)
$0.4260
+0.0034 ( +0.02% ) 610.3K
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Market Data
Open
$0.4260
Previous close
$0.4226
Volume
610.3K
Market cap
$22.15M
Day range
$0.3780 - $0.4420
52 week range
$0.2257 - $1.1500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Jun 07, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
10-q | Quarterly Reports | 91 | May 13, 2024 |
8-k | 8K-related | 15 | May 13, 2024 |
4 | Insider transactions | 1 | May 06, 2024 |
def | Proxies and info statements | 6 | Apr 22, 2024 |